Efficacy and safety of 48 weeks of guselkumab for patients with Crohn’s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial - Danese, S; Panaccione, R; Feagan, BG (Lancet Gastroenterol Hepatol, 2024)